Lung Toxicity Occurring During Enfortumab Vedotin Treatment: From a Priming Case Report to a Retrospective Analysis

Lung Toxicity Occurring During Enfortumab Vedotin Treatment: From a Priming Case Report to a Retrospective Analysis

<b>Background/Objectives:</b> Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) that combines monomethyl auristatin E (MMAE), a potent cytotoxic agent, with a monoclonal antibody targeting Nectin-4. It has emerged as a promising therapy for metastatic urothelial carcinoma (mUC)...

Full description

Saved in:
Bibliographic Details
Main Authors: Grégoire Desimpel, François Zammit, Sarah Lejeune, Guillaume Grisay, Emmanuel Seront
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Pharmaceuticals
Subjects:
antibody-drug conjugate
enfortumab vedotin
pneumopathy
corticosteroids
reversible
enfortumab vedotin discontinuation
Online Access:https://www.mdpi.com/1424-8247/17/11/1547
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1424-8247/17/11/1547

Similar Items